Evidence map›Paper›PMID 32848210›Full record

ArticleOncogene2020

HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers.

Shuling Ren, Daria A Gaykalova, Theresa Guo, Alexander V Favorov, Elana J Fertig, Pablo Tamayo, Juan Luis Callejas-Valera, Mike Allevato, Mara Gilardi, Jessica Santos and 13 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Targeting innate immunity to overcome immune evasion in HPV-associated cancers.Frontiers in cellular and infection microbiology · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 3 countries.

Shuling RenMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6886-3051
Daria A GaykalovaDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Theresa GuoDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Alexander V FavorovDivision of Oncology Biostatistics, Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Elana J FertigDivision of Oncology Biostatistics, Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Pablo TamayoDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9360-4668
Juan Luis Callejas-ValeraMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Mike AllevatoMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Mara GilardiMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Jessica SantosMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Takahito FukusumiMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Akihiro SakaiMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-1068-5061
Mizuo AndoMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Sayed SadatMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Chao LiuMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Guorong XuDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Kathleen M FischDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Zhiyong WangMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Alfredo A MolinoloMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
J Silvio GutkindMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-5150-4482
Trey IdekerDepartment of Medicine, University of California San Diego, La Jolla, CA, USA.
Wayne M KochDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Joseph A CalifanoMoores Cancer Center, University of California San Diego, La Jolla, CA, USA. jcalifano@ucsd.edu.ORCID http://orcid.org/0000-0002-4715-6761
University of California San Diego · USJohns Hopkins University · USCapital Medical University · CN

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
A Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic StatesU01CA217885 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COHEN, EZRA, KAUFMAN, DAN S. · 2017 to 2021
$5.1M
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6M
GenePattern and GenePattern Notebook: Integrative 'Omic Analysis for Cancer ResearchU24CA248457 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2020 to 2024
$4.6M
Next-generation Functional Genetic Screening of Un-screenable TraitsR01HG009285 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALI, PRASHANT, TAMAYO, PABLO · 2017 to 2020
$4.2M
Supporting and evolving Gene Set Enrichment Analysis and the Molecular Signatures Database for cancer researchU24CA220341 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2018 to 2022
$3.4M
GenePattern Notebooks for Cancer ResearchU24CA194107 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2015 to 2019
$2.8M
Delineating chromatin-related gene expression signatures as a function of HNSCC progressionR01DE027809 · NIDCR · UNIVERSITY OF MARYLAND BALTIMORE · PI GAYKALOVA, DARIA A, IZUMCHENKO, EVGENY (EUGENE) G · 2019 to 2023
$2.6M
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision TherapyR01DE026870 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2018 to 2022
$2.3M
Epigenetic Biomarker Discovery in HPV Related HNSCCR01DE023347 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CALIFANO, JOSEPH A · 2013 to 2017
$1.9M
Dynamical Models of Cetuximab Resistance in HNSCC Based on Serial Genomics DataR01CA177669 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2014 to 2019
$1.8M
NCATS NIH HHS UL1 TR001442NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA177669NCI NIH HHS U01 CA217885NCI NIH HHS U24 CA194107NCI NIH HHS U24 CA220341NCI NIH HHS U24 CA248457NHGRI NIH HHS R01 HG009285NIDCR NIH HHS R01 DE023347NIDCR NIH HHS R01 DE026870NIDCR NIH HHS R01 DE027809NIDCR NIH HHS RC1 DE020324NIDCR NIH HHS RC2 DE020789
6 · The paper itself

Abstract

The dominant paradigm for HPV carcinogenesis includes integration into the host genome followed by expression of E6 and E7 (E6/E7). We explored an alternative carcinogenic pathway characterized by episomal E2, E4, and E5 (E2/E4/E5) expression. Half of HPV positive cervical and pharyngeal cancers comprised a subtype with increase in expression of E2/E4/E5, as well as association with lack of integration into the host genome. Models of the E2/E4/E5 carcinogenesis show p53 dependent enhanced proliferation in vitro, as well as increased susceptibility to induction of cancer in vivo. Whole genomic expression analysis of the E2/E4/E5 pharyngeal cancer subtype is defined by activation of the fibroblast growth factor receptor (FGFR) pathway and this subtype is susceptible to combination FGFR and mTOR inhibition, with implications for targeted therapy.

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsCarcinogenesisCell Line, TumorCell ProliferationDatasets as TopicDisease-Free SurvivalDisease Models, AnimalFemaleGene Expression Regulation, NeoplasticGene Expression Regulation, ViralHost-Pathogen InteractionsHuman papillomavirus 16HumansMiceMice, TransgenicMTOR protein, humanOncogene Proteins, ViralReceptors, Fibroblast Growth FactorTOR Serine-Threonine KinasesTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID32848210
PMCPMC7529583
OpenAlexW3080640400

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.